Table 3.
Efficacy of lenvatinib on FGFR4 positive HCC (n = 40)
| FGFR4-ICH positive, n = 27 |
FGFR4-IHC negative, n = 13 |
|
|---|---|---|
| CR, n | 0 | 0 |
| PR, n | 22 | 4 |
| SD, n | 3 | 4 |
| PD, n | 2 | 5 |
| ORR, % | 81 | 31 |
| DCR, % | 93 | 62 |
| PFS, months | 5.5 | 2.5 |
IHC, immunohistochemical staining; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; HCC, hepatocellular carcinoma. Modified from ref. [22].